Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats

British Journal of Pharmacology

Volumn 117, Issue 6, 1996, Pages 1325-1333

  Nishimura, Yoshitaka ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT(1B) receptors; 5 HT1 like receptors; 5 HT2 receptors; 5 hydroxytryptamine (5 HT); Basilar artery; Stroke prone spontaneously hypertensive rat (SHRSP)

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2 METHYLSEROTONIN; 4 (4 METHYL 1 PIPERAZINYL) 7 TRIFLUOROMETHYLPYRROLO[1,2 A]QUINOXALINE; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (DIETHYLAMINO)ETHYL ESTER; 5 CARBAMOYLTRYPTAMINE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ALPHA METHYLSEROTONIN; ANGIOTENSIN; BEMESETRON; CISAPRIDE; COCAINE; ENDOTHELIN 1; INDOMETACIN; KETANSERIN; METITEPINE; NEUROPEPTIDE Y; PARGYLINE; PINDOLOL; PRAZOSIN; PROPRANOLOL; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2 RECEPTOR; SPIPERONE;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BASILAR ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STROKE;

EID: 0029965416     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb16732.x     Document Type: Article

References (43)

1. 1B receptor expression system. Mol. Pharmacol., 43, 427-433.
2. ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother., 14, 48-58.
3. 4 receptor: a place in the sun. Trends Pharmacol. Sci., 13, 141-145.
4. BONVENTO, G., MACKENZIE, E.T. & EDVINSSON, L. (1991). Serotonergic innervation of the cerebral vasculature: relevance to migraine and ischaemia. Brain Res. Rev., 16, 257-263.
5. BRADLEY, P.B., ENGEL, G., FENIUK, W., FOZARD, J.R., HUMPHREY, P.P.A., MIDDLEMISS, D.N., MYLECHARANE, E.J., RICHARDSON, B.P. & SAXENA, P.R. (1986). Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacol., 25, 563-576.
6. 4 receptors in the isolated guinea-pig ileum. Eur. J. Pharmacol., 200, 373-374.
7. CHANG, J.-Y., HARDEBO, J.E. & OWMAN, C.H. (1988). Differential vasomotor action of noradrenaline, serotonin, and histamine in isolated basilar artery from rat and guinea-pig. Acta Physiol. Scand., 132, 91-102.
8. CHANG, J.-Y. & OWMAN, C. (1987). Involvement of specific receptors and calcium mechanisms in serotonergic contractile responses of isolated cerebral and peripheral arteries from rats. J. Pharmacol. Exp. Ther., 242, 629-636.
9. 1-like receptor agonist. Br. J. Pharmacol., 96, 379-387.
10. 1B receptors mediate potent contractile responses to 5-HT in rat caudal artery. Br. J. Pharmacol., 109, 609-611.
11. 2 receptors predominantly mediate the contraction of the rat basilar artery to 5-hydroxytryptamine. Eur. J. Pharmacol., 221, 17-25.
12. 1D receptors of 5-hydroxytryptamine-induced contractions of rabbit middle and posterior cerebral arteries. Br. J. Pharmacol., 112, 939-945.
13. DESCOMBES, J.-J., DEVYS, M., LAUBIE, M. & VERBEUREN, T.J. (1993). Endothelial thromboxane production plays a role in the contraction caused by 5-hydroxytryptamine in rat basilar arteries. Eur. J. Pharmacol., 243, 193-199.
14. FOZARD, J.R. (1984). MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmied. Arch. Pharmacol., 326, 36-44.
15. FRENKEN, M. (1989). Evidence for two populations of 5-hydroxytryptamine receptors in dog basilar artery. J. Pharmacol. Exp. Ther., 250, 379-387.
16. FRENKEN, M. & KAUMANN, A.J. (1985). Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions of large coronary arteries of dog. Naunyn Schmied. Arch. Pharmacol., 328, 301-303.
17. GAW, A.J., WADSWORTH, R.M. & HUMPHREY, P.P.A. (1990). Pharmacological characterization of postjuctional 5-HT receptors in cerebral arteries from the sheep. Eur. J. Pharmacol., 179, 35-44.
18. GLUSA, E. & MÜLLER-SCHWEINITZER, E. (1993). Heterogeneity of 5-HT receptor subtypes in isolated human femoral and saphenous veins. Naunyn Schmied. Arch. Pharmacol., 347, 133-136.
19. 1D binding sites. Br. J. Pharmacol., 102, 227-233.
20. 1Dβ receptor subtype in human and bovine cerebral arteries. Mol. Pharmacol., 44, 242-246.
21. 1Dβ' receptors. Eur. J. Pharmacol., 242, 75-82.
22. HAMEL, E., ROBERT, J.-P., YOUNG, A.R. & MACKENZIE, E.T. (1989). Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery. J. Pharmacol. Exp. Ther., 249, 879-889.
23. HEISTAD, D.D. & BAUMBACH, G.L. (1992). Cerebral vascular changes during chronic hypertension: good guys and bad guys. J. Hypertension, 10, (Supple. 7) S71-S75.
24. HOYER, D., CLARKE, D.E., FOZARD, J.R., HARTIG, P.R., MARTIN, G.R., MYLECHARANE, E.J., SAXENA, P.R. & HUMPHREY, P.P.A. (1994). VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev., 46, 157-203.
25. HOYER, D. & SCHOEFFTER, P. (1991). 5-HT receptors: subtypes and second messengers. J. Recept. Res., 11, 197-214.
26. JANSEN, I., OLESEN, J. & EDVINSSON, L. (1993). 5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences. Acta Physiol. Scand., 147, 141-150.
27. KENAKlN, T. (1993). Pharmacological Analysis of Drug-Receptor Interaction, pp. 278-322. New York: Raven Press.
28. MIYAMOTO, A., SAKOTA, T. & NISHIO, A. (1994). Characterization of 5-hydroxytryptamine receptors on the isolated pig basilar artery by functional and radioligand binding studies. Jpn. J. Pharmacol., 65, 265-273.
29. NAKANE, T., KAWAI, K. & CHIBA, S. (1993). Mechanism of pindolol-induced vasoconstriction in isolated and perfused dog coronary arteries. Jpn. J. Pharmacol., 62, 67-74.
30. NEALE, R.F., FALLON, S.L., BOYAR, W.C., WASLEY, J.W.F., MARTIN, L.L., STONE, G.A., GLAESER, B.S., SINTON, C.M. & WILLIAMS, M. (1987). Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur. J. Pharmacol., 136, 1-9.
31. NISHIMURA, Y., USUI, H., SUZUKI, A., KAJIMOTO, N. & YAMANISHI, Y. (1992). Relaxant response of isolated basilar arteries to calcitonin gene-related peptide in stroke-prone spontaneously hypertensive rats. Jpn. J. Pharmacol., 59, 333-338.
32. OGLETREE, M.L., HARRIS, D.N., GREENBERG, R., HASLANGER, M.F. & NAKANE, M. (1985). Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther., 234, 435-441.
33. 1-like receptors in rabbit isolated basilar arteries. Eur. J. Pharmacol., 174, 189-196.
34. 1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br. J. Pharmacol., 96, 434-449.
35. 1A receptors. J. Pharmacol. Exp. Ther., 237, 901-906.
36. SAXENA, P.R. (1989). Cardiovascular effects from stimulation of 5-hydroxytryptamine receptors. Fundam. Clin. Pharmacol., 3, 245-265.
37. 1B receptor ligands exist? Naunyn Schmied. Arch. Pharmacol., 339, 675-683.
38. 1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some β-adrenoceptor antagonists. Naunyn Schmied. Arch. Pharmacol., 340, 285-292.
39. SOLTIS, E.E. & BOHR, D.F. (1987). Cerebral vascular responsiveness in deoxycorticosterone acetate-salt hypertensive rats. Am. J. Physiol., 252, H198-H203.
40. 1B receptor in opossum kidney cells after exposure to agonists. Mol. Pharmacol. 42, 464-470.
41. VAN ZWIETEN, P.A. (1987). Pathophysiological relevance of serotonin. J. Cardiovasc. Pharmacol., 10, (Suppl. 3), S19-S25.
42. WINQUIST, R.J. & BOHR, D.F. (1983). Structural and functional changes in cerebral arteries from spontaneously hypertensive rats. Hypertension, 5, 292-297.
43. YOKOTA, Y., IMAIZUMI, Y., ASANO, M., MATSUDA, T. & WATANABE, M. (1994). Endothelium-derived relaxing factor released by 5-HT: distinct from nitric oxide in basilar arteries of normotensive and hypertensive rats. Br. J. Pharmacol., 113, 324-330.